Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Acquisitions & Divestments (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Change in Acquisitions & Divestments for 9 consecutive years, with $19.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 53.62% year-over-year to $19.9 million, compared with a TTM value of $72.0 million through Dec 2025, up 28.96%, and an annual FY2025 reading of $72.0 million, up 28.96% over the prior year.
  • Change in Acquisitions & Divestments was $19.9 million for Q4 2025 at Puma Biotechnology, down from $27.3 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $27.3 million in Q3 2025 and bottomed at -$37000.0 in Q4 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $10.1 million, with a median of $9.0 million recorded in 2022.
  • The sharpest move saw Change in Acquisitions & Divestments plummeted 100.8% in 2022, then skyrocketed 8686.49% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $4.6 million in 2021, then crashed by 100.8% to -$37000.0 in 2022, then surged by 8686.49% to $3.2 million in 2023, then surged by 308.25% to $13.0 million in 2024, then surged by 53.62% to $19.9 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for PBYI at $19.9 million in Q4 2025, $27.3 million in Q3 2025, and $10.7 million in Q2 2025.